Discover personalized clinical trial options designed to support your journey, safely, confidentially, and at no cost.
Takes less than 2 minutes • 100% confidential
Alzheimer's Disease is a significant health condition affecting 55M people globally. Research is ong…
Condition-specific symptoms, Consult a specialist, Early diagnosis advised and more.
Genetic and hereditary factors; Environmental exposures.
Medical Management, Lifestyle Modifications and more.
Symptoms
Common Symptoms
Quality of Life Impact
Managing this condition with proper medical care can significantly improve quality of life. A coordinated care team approach is recommended.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
21+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
Evidence-based medications tailored to disease severity and patient profile.
Diet, exercise, and behavioral interventions as appropriate.
Regular follow-up with a specialist in this condition.
Clinical Trials
43 trials identified in worldwide registries
HEKMA is currently curating these for direct matching. Check back soon, or browse all trials on ClinicalTrials.gov.
Daily Life
You are not alone. Millions of people navigate this condition every day, and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Why Join a Trial
Try innovative therapies before they're widely available, some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Alzheimer's Disease
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
News
Lecanemab Receives Full FDA Approval for Early Alzheimer's Disease
The FDA granted traditional (full) approval to lecanemab (Leqembi) for early Alzheimer's disease, following confirmatory Phase 3 data showing 27% slowing of cognitive decline.
FDA · Mar 5, 2025
FAQ
Resources
NIH MedlinePlus
Authoritative overview of Alzheimer's Disease from the National Institutes of Health.
Visit NIH →
Alzheimer's Disease Foundation
Patient advocacy resources, support groups, and disease education.
Visit Foundation →
Emergency Guide
What to do in an emergency, share with family.
Download Guide →
